PT-141

PT-141 is the development code for bremelanotide, a synthetic peptide modeled on alpha-melanocyte-stimulating hormone (α-MSH). It activates melanocortin receptors, mainly MC3R and MC4R, part of the receptor family involved in appetite, skin pigmentation, and sexual behavior ¹.

The FDA approved bremelanotide in June 2019 as Vyleesi, an on-demand subcutaneous injection for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women ⁹. It is one of more than 20 FDA-approved drugs built with D-amino acids, an unusual structural choice that makes the peptide resistant to breakdown by enzymes ¹¹.

Most research centers on female HSDD. The strongest evidence comes from two Phase 3 trials known as RECONNECT ³, though independent reanalysis has questioned how large the benefit really is ⁴. Earlier development also tested intranasal and injected PT-141 in men with erectile dysfunction ², and smaller bodies of research explore effects on body weight ¹⁹ and on cancer cells ²⁰.

PT-141 works in the brain, not in the blood vessels of the genitals. Unlike PDE5 inhibitors such as sildenafil, which relax blood vessels to enable erection, PT-141 increases sexual desire and subjective arousal through central melanocortin signaling ³. In the first controlled trial in women, the drug improved desire and satisfaction with arousal while measurable vaginal blood flow did not change ¹.

The drug is a synthetic analog of α-MSH that binds and activates MC3R and MC4R ¹. Its cellular effects are blocked by an MC3R/MC4R antagonist, confirming the receptor pair as the target ²⁰. These receptors influence many systems at once: appetite, stress response, energy balance, and pigmentation ¹².

Where in the brain

In female hamsters, MC4R is concentrated on dopamine neurons in the ventral tegmental area (VTA), a region linked to motivation and reward ¹³. Yet bremelanotide did not change receptor expression there and did not enhance sexual reward in those animals. That points toward hypothalamic pathways that connect to autonomic and hormonal outputs, rather than a classic reward-circuit effect ¹³.

Why effects outlast blood levels

The peptide survives digestion because it contains D-amino acids, which slow protease cleavage ¹¹. Its molecular weight is about 1.03 kDa ²⁵. After subcutaneous dosing, blood levels clear within hours, while reported effects can persist for up to about 12 hours, which fits central receptor engagement rather than sustained circulation (practitioner consensus).

Sexual desire and distress in women

Two Phase 3 trials (RECONNECT) in premenopausal women with HSDD reported improvements in desire on the Female Sexual Function Index and reduced distress about low desire ³. A 2026 meta-analysis concluded bremelanotide improves total FSFI scores, desire and arousal subscales, and distress ⁷. Independent reanalysis of the same trial data found nil-to-small effect sizes and questioned the measurement tools, a critique the original investigators dispute ⁴.

Sexual arousal

In an early crossover trial, a single 20 mg intranasal dose increased reports of moderate or high sexual desire and satisfaction with arousal in women with sexual arousal disorder, with no change in vaginal blood flow on photoplethysmography ¹.

Erectile function in men

Phase 1 studies in healthy men and in men with an inadequate response to sildenafil documented erectogenic signals with subcutaneous PT-141 ², and low-dose intranasal PT-141 added to sildenafil enhanced erectile response ²³. The one randomized trial pitched as salvage therapy for sildenafil failures later received a journal Expression of Concern, so male use remains investigational ²¹.

Exploratory signals

Two Phase 1 trials in obese women generated exploratory body-weight data ¹⁹. In cell culture, bremelanotide suppressed survivin, a protein that helps cancer cells survive, induced death of glioblastoma cells, and sensitized them to temozolomide and osimertinib ²⁰. These findings are early and are not approved indications.

Approved dosing

The approved regimen is 1.75 mg subcutaneously in the abdomen or thigh, on demand, at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and a maximum of 8 doses per month ²⁷. The label directs stopping after 8 weeks if there is no benefit ²⁷.

Clinical trial dosing

The Phase 3 RECONNECT trials used 1.75 mg subcutaneously as needed for 24 weeks, followed by an open-label extension of up to 52 weeks ³. Phase 2b dose-finding established that lower fixed doses were suboptimal, and responder analyses supported the 1.75 mg registration dose ²⁹. Older intranasal studies used a 20 mg single dose in women ¹ and pharmacokinetic-evaluated doses in men ²⁴.

Community protocols

Community protocols for male sexual dysfunction commonly use 0.5 to 2 mg subcutaneously on demand, 30 to 60 minutes before activity, with a 1 mg test dose first to gauge nausea and doses spaced at least 72 hours apart to limit tolerance. Practitioner scaling by body weight (roughly 0.02 to 0.03 mg/kg) is extrapolation rather than a validated clinical rule. Above about 2.5 to 3 mg, nausea and blood-pressure effects tend to outweigh added benefit.

Cycle structure

PT-141 is an as-needed drug rather than a cycle-dependent one. Registrational exposure ran 24 weeks double-blind plus a 52-week open-label extension with no evidence of tolerance ³. Daily dosing is not used, reflecting the 24-hour dose cap ²⁷, the blood-pressure burden ¹⁶, and nausea ³⁵.

The commercial product (Vyleesi) is a ready-to-use single-dose autoinjector containing 1.75 mg per 0.3 mL, so the approved formulation requires no preparation ²⁷. Research-grade PT-141, by contrast, is supplied as lyophilized (freeze-dried) powder and must be reconstituted before injection.

Protocols call for bacteriostatic water (0.9% benzyl alcohol) when multiple withdrawals are planned, or sterile water for an immediate single use. The diluent is added slowly down the vial wall and the vial swirled gently; shaking or vortexing is avoided because mechanical stress can damage the peptide.

• Powder storage: frozen at about -20°C long term, or refrigerated for weeks to months, protected from light and moisture.
• Solution storage: refrigerated at 2 to 8°C and never frozen. Shelf life with bacteriostatic water is commonly cited as 30 to 60 days; sterile-water solutions are used within 24 hours.
• Autoinjector storage: refrigerated per the manufacturer label, protected from light ²⁷.

The peptide resists enzyme breakdown thanks to its D-amino acid content ¹¹, but it still degrades chemically in solution. Analytical studies have characterized bremelanotide degradants and predicted epimerization ³⁶, so minimizing time in solution and avoiding repeated freeze-thaw cycles matters. Any vial with particles or cloudiness after reconstitution is discarded. Use the interactive calculator in this section to work out diluent volumes and concentrations.

Alcohol

A Phase 1 double-blind RCT tested bremelanotide coadministered with ethanol in healthy participants and found the combination increases nausea and vomiting ¹⁷. The label carries a drug-interaction warning about alcohol use around administration, not a formal contraindication ²⁷.

PDE5 inhibitors

Low-dose intranasal PT-141 plus sildenafil enhanced erectile response in men with ED in a placebo-controlled combination study ²³. The mechanisms are complementary: central MC4R activation plus peripheral blood-vessel relaxation. The later PDE5 salvage trial carries an Expression of Concern, so the evidence base leans on the earlier combination data ²¹. The usual PDE5 inhibitor caution about nitrates still applies.

Blood pressure medications

Ambulatory monitoring documented a transient pressor response of about +6 mmHg systolic and +3 mmHg diastolic versus placebo, peaking 2 to 8 hours after dosing ¹⁶. Uncontrolled hypertension is a labeled contraindication ²⁷. Research protocols call for blood-pressure measurement in the hours after the first several doses when antihypertensives are involved.

Antiemetics

Nausea is the most frequent adverse event across the development program ³⁵. Community protocols pair dosing with an ondansetron-class antiemetic 30 to 60 minutes beforehand.

Other considerations

• Melanotan II: both are melanocortin agonists, and black-market products are often mislabeled or mixed ²⁶; combining stacks nausea and pigmentation risk.
• CYP drugs: bremelanotide is cleared by peptidases rather than liver CYP enzymes, so interactions with CYP inhibitors or inducers are unlikely ¹¹.
• Sympathomimetics: plausible additive blood-pressure and heart-rate effects on top of the transient pressor response ¹⁶.
• GLP-1 agonists: both suppress appetite and can cause nausea; community protocols separate injection timing and add an antiemetic.

With PDE5 inhibitors

The best-documented combination is PT-141 with sildenafil: central desire signaling meets peripheral vasodilation, and the combination trial showed an enhanced erectile response versus sildenafil alone ²³. Early subcutaneous studies also enrolled men who had responded inadequately to sildenafil ². Combined use in men carries the usual PDE5-class priapism risk, and an erection lasting more than 4 hours requires immediate medical attention.

With kisspeptin-10

Kisspeptin-10 acts on a different receptor (KISS1R) and independently facilitates copulatory behavior in male rats ¹⁵. The combination is unstudied; effects are plausibly additive without direct antagonism.

With GLP-1 agonists

Bremelanotide reduced body weight in two Phase 1 trials in obese women ¹⁹, so combining with semaglutide or tirzepatide stacks appetite suppression and nausea. Community protocols add an antiemetic and separate injection timing.

Common co-administration

• BPC-157 and TB-500: no expected interaction; commonly co-dosed in community practice.
• GH secretagogues (ipamorelin, CJC-1295): no mechanistic overlap; flushing and pressor effects may stack mildly.
• Melanotan II: not combined. Both are melanocortin agonists, and the combination multiplies nausea, pigmentation, and erection-related risk ²⁶.

No randomized trial has tested a multi-peptide stack containing PT-141. The rationale above is built from single-compound data and mechanism (practitioner consensus).

United States

Bremelanotide was approved by the FDA in June 2019 as Vyleesi for acquired, generalized HSDD in premenopausal women ⁹. It and flibanserin are the only FDA-approved drugs for this indication ¹⁰. Approval was based on the RECONNECT Phase 3 program ³, and the drug is counted among the more than 20 approved pharmaceuticals containing D-amino acids ¹¹.

The indication is narrow: there is no approval for men, for postmenopausal women, or for any other use. The sole randomized salvage trial in men carries an Expression of Concern ²¹, and a 2008 female-arousal trial from the same group was retracted ⁴¹. Investigational programs outside HSDD include Phase 1 obesity RCTs ¹⁹.

Bremelanotide is not controlled under the Controlled Substances Act, but it is prescription-only. The approved autoinjector is distributed through specialty pharmacy channels. Unregulated PT-141 sold as a research peptide is documented on the performance-enhancement black market via LC-HRMS ²⁶; sale for human use would be an unapproved new drug under federal law.

Outside the US

No EMA, MHRA, or TGA marketing authorization is documented in the available evidence, so the regulatory footprint outside the US is limited. Canadian and US cancer-survivorship guidelines list bremelanotide among pharmacologic options for low desire, with limited data ³⁷.

Sports

PT-141 is not on the WADA Prohibited List, and no Therapeutic Use Exemption is required, per current practitioner consensus. The related unapproved analog melanotan II is prohibited under category S0 as a non-approved substance.

Common side effects

Nausea is the signature side effect, reported by about 40% of treated women versus roughly 1% on placebo in the RECONNECT trials ³. Flushing follows at about 20%, with injection-site reactions (~13%), headache (~11%), and vomiting (~5%) ³. About 18% of treated women discontinued because of an adverse event, mostly nausea, versus about 2% on placebo ³⁵. Exit interviews confirm nausea is the main reason women stop treatment ³⁹. Nausea typically appears with the first doses and fades with repeated exposure.

Blood pressure

Ambulatory monitoring recorded transient increases of about 6 mmHg systolic and 3 mmHg diastolic versus placebo, peaking 2 to 8 hours after injection ¹⁶. Uncontrolled hypertension and known cardiovascular disease are contraindications ²⁷. Long-term cardiovascular outcome data are not available ¹⁶. The same ambulatory monitoring documented a transient reduction in heart rate accompanying the pressor response, which warrants caution in people with baseline bradycardia, conduction abnormalities, or who take rate-lowering medications ¹⁶.

Skin pigmentation

Focal skin darkening, occasionally involving the gums, is uncommon, is mediated by the MC1R receptor, and appeared in the long-term extension; it can persist after discontinuation ¹². MC1R variation is linked to melanoma risk, which makes chronic pigmentation effects worth watching ¹².

Tolerability over time

A 52-week open-label extension reported no new safety signals with as-needed use ¹⁸. The early 20 mg intranasal formulation produced subjective desire without measurable vaginal blood-flow changes, consistent with a central effect profile ¹.

Research caveats

Safety reporting across HSDD trials has been inconsistent, which limits how precisely adverse-event rates can be pooled ⁸. Formal interaction studies exist for ethanol ¹⁷, but not for antihypertensives, antidepressants, or PDE5 inhibitors. Black-market products have been analytically confirmed to contain bremelanotide, but purity is not guaranteed outside regulated supply ²⁶.